目的 分析艾迪注射液輔助治療腫瘤的臨床應(yīng)用現(xiàn)狀，探尋艾迪注射液輔助治療腫瘤的用藥規(guī)律及療效特征。方法 檢索1989年1月—2020年12月中國(guó)期刊全文數(shù)據(jù)庫(kù)（CNKI）、萬(wàn)方數(shù)字化期刊全文庫(kù)、中文科技期刊全文數(shù)據(jù)庫(kù)（維普）報(bào)道的艾迪注射液治療腫瘤相關(guān)文獻(xiàn)，進(jìn)行資料的提取與統(tǒng)計(jì)分析。結(jié)果 以“益佰牌”艾迪注射液為例，共納入文獻(xiàn)169篇，涉及病例數(shù)14 050例，多為100人以下的小規(guī)模研究，報(bào)道的腫瘤類型以肺癌最多，多以有效率提高、KPS評(píng)分改善、不良反應(yīng)發(fā)生率減少、臨床癥狀改善、免疫功能增強(qiáng)、一年生存率提高及CEA、AFP等生化指標(biāo)改善作為臨床療效的評(píng)價(jià)指標(biāo)。結(jié)論 基于回顧性文獻(xiàn)分析發(fā)現(xiàn)艾迪注射液臨床應(yīng)用廣泛，療效確切，在減少化療副作用基礎(chǔ)上，可提高患者的生活質(zhì)量，但文獻(xiàn)質(zhì)量不是很高，作為證據(jù)級(jí)別尚顯不夠，值得臨床進(jìn)一步深入研究。

Objective To analyze the current status of the clinical application of Aidi Injection in adjuvant treatment of tumors, and explore the drug administration rules and efficacy characteristics of Aidi Injection in the treatment of tumors. Methods China Journal Full-text Database (CNKI), Wanfang Database, Chinese Science and Technology Journal Full-text Database (VIP) were retrieved from January 1989 to December 2020, and the literature involving cases were extracted and analyzed. Results Taking “Yibai” Aidi Injection as an example, a total of 169 articles were included, involving a small-scale study of 14 050 cases and mostly less than 100 people. The most reported types of tumor were lung cancer. Improved efficiency, KPS score improvement, reduction of incidence of adverse reactions, improvement of clinical symptoms, enhancement of immune function, improvement of one-year survival rate, and improvement of physical and chemical indicators such as CEA and AFP were used as evaluation indicators of clinical efficacy. Conclusion Based on literature analysis, it is found that Aidi Injection has a wide range of clinical application and exact effect. It can improve the quality of life of patients on the basis of reducing the side effects of chemotherapy, but the quality of the literature is not very high, and the level of evidence is not enough. It is worth further clinical research.

R979.1